Adragos Pharma Expands Global Reach with Acquisition of Swiss CDMO Baccinex

Acquisition:
Adragos Pharma has acquired Baccinex, a Swiss-based Contract Development and Manufacturing Organization (CDMO) specializing in aseptic fill-finish services[1][3].

Expansion:
The acquisition significantly expands Adragos Pharma's capacity in sterile drug production and enhances its competitiveness in global markets[2][4].

Manufacturing Sites:
Baccinex's Swiss plant becomes Adragos Pharma's sixth manufacturing site, joining its existing facilities in Europe and Japan[4].

Expertise:
Baccinex has over 20 years of experience in aseptic fill-finish services for liquid and lyophilized vials[1].

Global Impact:
The acquisition strengthens Adragos Pharma's leadership in aseptic fill-finish across Europe, Japan, and global markets[2].